Terms: = Prostate cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
27 results:
1. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
2. Enzalutamide Reduces Oxycodone Exposure in Men with prostate cancer.
Detert Oude Weme SEH; Hulskotte LMG; Vervenne WL; Imholz ALT; Cremers RGHM; Taxis K; Reyners AKL; van Berlo-van de Laar IRF; Jansman FGA; Benoist GE
Clin Pharmacokinet; 2023 Jul; 62(7):989-996. PubMed ID: 37162620
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Polymorphisms of Cytochromes P450 in Finno-Permic Populations of Russia.
Dzhaubermezov M; Ekomasova N; Mustafin R; Gabidullina L; Galimova Y; Nurgalieva A; Valova Y; Prokofyeva D; Khusnutdinova E
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553620
[TBL] [Abstract] [Full Text] [Related]
4. Splice-disrupt genomic variants in prostate cancer.
Alanazi IO; Alamery SF; Ebrahimie E; Mohammadi-Dehcheshmeh M
Mol Biol Rep; 2022 Jun; 49(6):4237-4246. PubMed ID: 35286517
[TBL] [Abstract] [Full Text] [Related]
5. 3,4-Dihydropyrimidin-2(1
Majellaro M; Jespers W; Crespo A; Núñez MJ; Novio S; Azuaje J; Prieto-Díaz R; Gioé C; Alispahic B; Brea J; Loza MI; Freire-Garabal M; Garcia-Santiago C; Rodríguez-García C; García-Mera X; Caamaño O; Fernandez-Masaguer C; Sardina JF; Stefanachi A; El Maatougui A; Mallo-Abreu A; Åqvist J; Gutiérrez-de-Terán H; Sotelo E
J Med Chem; 2021 Jan; 64(1):458-480. PubMed ID: 33372800
[TBL] [Abstract] [Full Text] [Related]
6. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function cyp2d6 alleles.
Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
[TBL] [Abstract] [Full Text] [Related]
7. Cytochrome P450: Polymorphisms and Roles in cancer, Diabetes and Atherosclerosis.
Elfaki I; Mir R; Almutairi FM; Duhier FMA
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2057-2070. PubMed ID: 30139042
[TBL] [Abstract] [Full Text] [Related]
8. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract] [Full Text] [Related]
9. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Del Re M; Fogli S; Derosa L; Massari F; De Souza P; Crucitta S; Bracarda S; Santini D; Danesi R
Cancer Treat Rev; 2017 Apr; 55():71-82. PubMed ID: 28340451
[TBL] [Abstract] [Full Text] [Related]
10. Promising Tools in prostate cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract] [Full Text] [Related]
11. [Treatment of metastatic castration-resistant prostate cancer : Drug interaction potentials of abiraterone acetate and enzalutamide].
Lipp HP; Miller K
Urologe A; 2016 Jun; 55(6):766-71. PubMed ID: 26927871
[TBL] [Abstract] [Full Text] [Related]
12. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.
Chi KN; Tolcher A; Lee P; Rosen PJ; Kollmannsberger CK; Papadopoulos KP; Patnaik A; Molina A; Jiao J; Pankras C; Kaiser B; Bernard A; Tran N; Acharya M
Cancer Chemother Pharmacol; 2013 Jan; 71(1):237-44. PubMed ID: 23064959
[TBL] [Abstract] [Full Text] [Related]
13. Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Prescrire Int; 2012 Jun; 21(128):147-9. PubMed ID: 22822591
[TBL] [Abstract] [Full Text] [Related]
14. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.
Kim J; Peraire C; Solà J; Johanning KM; Dalton JT; Veverka KA
Xenobiotica; 2011 Oct; 41(10):851-62. PubMed ID: 21726172
[TBL] [Abstract] [Full Text] [Related]
15. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
Sonesson A; Rasmussen BB
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
[TBL] [Abstract] [Full Text] [Related]
16. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Deeken JF; Cormier T; Price DK; Sissung TM; Steinberg SM; Tran K; Liewehr DJ; Dahut WL; Miao X; Figg WD
Pharmacogenomics J; 2010 Jun; 10(3):191-9. PubMed ID: 20038957
[TBL] [Abstract] [Full Text] [Related]
17. CYP17, SRD5A2, CYP1B1, and cyp2d6 gene polymorphisms with prostate cancer risk in North Indian population.
Sobti RC; Onsory K; Al-Badran AI; Kaur P; Watanabe M; Krishan A; Mohan H
DNA Cell Biol; 2006 May; 25(5):287-94. PubMed ID: 16716118
[TBL] [Abstract] [Full Text] [Related]
18. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.
Damaraju S; Murray D; Dufour J; Carandang D; Myrehaug S; Fallone G; Field C; Greiner R; Hanson J; Cass CE; Parliament M
Clin Cancer Res; 2006 Apr; 12(8):2545-54. PubMed ID: 16638864
[TBL] [Abstract] [Full Text] [Related]
19. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
Fukatsu T; Hirokawa Y; Araki T; Hioki T; Murata T; Suzuki H; Ichikawa T; Tsukino H; Qiu D; Katoh T; Sugimura Y; Yatani R; Shiraishi T; Watanabe M
Anticancer Res; 2004; 24(4):2431-7. PubMed ID: 15330195
[TBL] [Abstract] [Full Text] [Related]
20. Cytochrome P450 gene polymorphism and cancer.
Agundez JA
Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
[TBL] [Abstract] [Full Text] [Related]
[Next]
